These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 34569489)

  • 1. Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial.
    Yamamoto H; Nobori K; Matsuda Y; Hayashi Y; Hayasaki T; Akizawa T
    Am J Nephrol; 2021; 52(10-11):871-883. PubMed ID: 34569489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study.
    Yamamoto H; Nobori K; Matsuda Y; Hayashi Y; Hayasaki T; Akizawa T
    Am J Nephrol; 2021; 52(10-11):884-893. PubMed ID: 34569482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies.
    Yamamoto H; Taguchi M; Matsuda Y; Iekushi K; Yamada T; Akizawa T
    BMJ Open; 2019 Jun; 9(6):e026704. PubMed ID: 31203242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Molidustat in the Treatment of Anemia in CKD.
    Macdougall IC; Akizawa T; Berns JS; Bernhardt T; Krueger T
    Clin J Am Soc Nephrol; 2019 Jan; 14(1):28-39. PubMed ID: 30559105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Efficacy and Safety of Molidustat for Anemia in Chronic Kidney Disease: DIALOGUE Extension Studies.
    Akizawa T; Macdougall IC; Berns JS; Bernhardt T; Staedtler G; Taguchi M; Iekushi K; Krueger T
    Am J Nephrol; 2019; 49(4):271-280. PubMed ID: 30852574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molidustat for Japanese Patients With Renal Anemia Receiving Dialysis.
    Akizawa T; Yamada T; Nobori K; Matsuda Y; Hayashi Y; Hayasaki T; Yamamoto H
    Kidney Int Rep; 2021 Oct; 6(10):2604-2616. PubMed ID: 34622100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: design and rationale of three phase III studies.
    Akizawa T; Taguchi M; Matsuda Y; Iekushi K; Yamada T; Yamamoto H
    BMJ Open; 2019 Jun; 9(6):e026602. PubMed ID: 31203241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial.
    Singh AK; Cizman B; Carroll K; McMurray JJV; Perkovic V; Jha V; Johansen KL; Lopes RD; Macdougall IC; Obrador GT; Waikar SS; Wanner C; Wheeler DC; Wiecek A; Stankus N; Strutz F; Blackorby A; Cobitz AR; Meadowcroft AM; Paul G; Ranganathan P; Sedani S; Solomon S
    JAMA Intern Med; 2022 Jun; 182(6):592-602. PubMed ID: 35377393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia: A Randomized, Double-Blind, Phase 3 Trial.
    Akizawa T; Nangaku M; Yonekawa T; Okuda N; Kawamatsu S; Onoue T; Endo Y; Hara K; Cobitz AR
    Clin J Am Soc Nephrol; 2020 Aug; 15(8):1155-1165. PubMed ID: 32723804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molidustat for anemia correction in Japanese patients undergoing hemodialysis: a single-arm, phase 3 study.
    Akizawa T; Nobori K; Matsuda Y; Hayashi Y; Hayasaki T; Yamamoto H
    Ther Apher Dial; 2021 Dec; 25(6):917-925. PubMed ID: 33506635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron Regulation by Molidustat, a Daily Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, in Patients with Chronic Kidney Disease.
    Akizawa T; Macdougall IC; Berns JS; Yamamoto H; Taguchi M; Iekushi K; Bernhardt T
    Nephron; 2019; 143(4):243-254. PubMed ID: 31387097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Darbepoetin alfa injection versus epoetin alfa injection for treating anemia of Chinese hemodialysis patients with chronic kidney failure: A randomized, open-label, parallel-group, non-inferiority Phase III trail.
    Chen N; Xing C; Niu J; Liu B; Fu J; Zhao J; Ni Z; Wang M; Liu W; Zhao J; Zhong L; Wu X; Li W; Chen Y; Shi W; Chen J; Yin A; Fu P; Wang R; Jiang G; Hou F; Ding G; Chen J; Xu G; Kondo Y; Su Y; Mei C
    Chronic Dis Transl Med; 2022 Mar; 8(1):59-70. PubMed ID: 35620165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment satisfaction with molidustat in CKD-related anemia in non-dialysis patients: a post-hoc analysis of two clinical trials.
    Yamamoto H; Yamada T; Miyazaki K; Yamashita T; Kato T; Ohara K; Nakamura Y; Akizawa T
    Clin Exp Nephrol; 2023 Aug; 27(8):651-659. PubMed ID: 37095342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis.
    Akizawa T; Yamaguchi Y; Otsuka T; Reusch M
    Nephron; 2020; 144(8):372-382. PubMed ID: 32580188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a Phase 3, multicenter, randomized, double-blind study.
    Nangaku M; Kondo K; Ueta K; Kokado Y; Kaneko G; Matsuda H; Kawaguchi Y; Komatsu Y
    Nephrol Dial Transplant; 2021 Aug; 36(9):1731-1741. PubMed ID: 33650630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open-Label Study.
    Akizawa T; Otsuka T; Reusch M; Ueno M
    Ther Apher Dial; 2020 Apr; 24(2):115-125. PubMed ID: 31222951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molidustat for the treatment of anemia in Japanese patients undergoing peritoneal dialysis: a single-arm, open-label, phase 3 study.
    Akizawa T; Nobori K; Matsuda Y; Taki K; Hayashi Y; Hayasaki T; Yamamoto H
    Ther Apher Dial; 2022 Apr; 26(2):368-377. PubMed ID: 34310049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial.
    Macdougall IC; Walker R; Provenzano R; de Alvaro F; Locay HR; Nader PC; Locatelli F; Dougherty FC; Beyer U;
    Clin J Am Soc Nephrol; 2008 Mar; 3(2):337-47. PubMed ID: 18287255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. De novo weekly and biweekly darbepoetin alfa dosing in pediatric patients with chronic kidney disease.
    Warady BA; Barcia J; Benador N; Jankauskiene A; Olson K; Podracka L; Shavkin A; Srivaths P; Wong CJ; Petersen J
    Pediatr Nephrol; 2018 Jan; 33(1):125-137. PubMed ID: 28815341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan.
    Akizawa T; Iwasaki M; Yamaguchi Y; Majikawa Y; Reusch M
    J Am Soc Nephrol; 2020 Jul; 31(7):1628-1639. PubMed ID: 32493693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.